Analysts predict that Glaukos Corp (NYSE:GKOS) will report sales of $40.71 million for the current quarter, according to Zacks. Three analysts have made estimates for Glaukos’ earnings, with the highest sales estimate coming in at $41.23 million and the lowest estimate coming in at $39.80 million. Glaukos reported sales of $33.17 million in the same quarter last year, which indicates a positive year-over-year growth rate of 22.7%. The company is scheduled to issue its next earnings report after the market closes on Wednesday, February 28th.
On average, analysts expect that Glaukos will report full year sales of $40.71 million for the current fiscal year, with estimates ranging from $157.70 million to $159.00 million. For the next financial year, analysts anticipate that the company will post sales of $174.12 million per share, with estimates ranging from $168.50 million to $185.20 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Glaukos.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. ValuEngine lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Cantor Fitzgerald set a $48.00 price target on shares of Glaukos and gave the stock a “buy” rating in a research note on Wednesday, January 10th. BMO Capital Markets reaffirmed a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Finally, Stephens reaffirmed an “overweight” rating and issued a $40.00 price target (down from $47.00) on shares of Glaukos in a research note on Monday, November 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $44.86.
A number of hedge funds have recently added to or reduced their stakes in GKOS. Handelsbanken Fonder AB raised its holdings in shares of Glaukos by 16.8% during the fourth quarter. Handelsbanken Fonder AB now owns 188,000 shares of the medical instruments supplier’s stock valued at $4,822,000 after acquiring an additional 27,000 shares during the period. William Blair Investment Management LLC raised its holdings in shares of Glaukos by 7.5% during the fourth quarter. William Blair Investment Management LLC now owns 1,979,960 shares of the medical instruments supplier’s stock valued at $50,786,000 after acquiring an additional 137,969 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Glaukos during the fourth quarter valued at approximately $349,000. Macquarie Group Ltd. raised its holdings in shares of Glaukos by 33.7% during the fourth quarter. Macquarie Group Ltd. now owns 50,530 shares of the medical instruments supplier’s stock valued at $1,296,000 after acquiring an additional 12,750 shares during the period. Finally, Meadow Creek Investment Management LLC acquired a new stake in shares of Glaukos during the fourth quarter valued at approximately $336,000.
Shares of Glaukos (NYSE:GKOS) traded up $0.22 during trading hours on Tuesday, hitting $31.27. 194,989 shares of the company were exchanged, compared to its average volume of 429,124. The company has a market cap of $1,080.51, a P/E ratio of -781.55, a PEG ratio of 45.30 and a beta of 1.21. Glaukos has a twelve month low of $23.08 and a twelve month high of $52.49.
COPYRIGHT VIOLATION NOTICE: “$40.71 Million in Sales Expected for Glaukos Corp (GKOS) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/23/40-71-million-in-sales-expected-for-glaukos-corp-gkos-this-quarter.html.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Get a free copy of the Zacks research report on Glaukos (GKOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.